title: [New drugs for treatment of tuberculosis].
abstract: New effective drugs for the treatment of tuberculosis (TB) are necessary for two main reasons: firstly, it would be desirable to reduce the duration of TB treatment from 6 to 4 months and secondly, new drugs are urgently needed for the treatment of multidrug-resistant strains of Mycobacterium tuberculosis. For the first time since 1960 the two new drugs bedaquiline and delamanid were approved and licensed in 2014 for the treatment of multidrug-resistant M. tuberculosis; however, efforts to reduce the duration of treatment to 4 months using fluoroquinolones have not been successful. Further new drugs are currently in phase 2 and phase 3 studies; therefore, new treatment options can be expected within the next few years.
authors.affiliation: Zentrum für Pneumologie, Agaplesion Diakonieklinikum Rotenburg, Elise-Averdieck-Str. 17, 27356, Rotenburg, Deutschland. schaberg@diako-online.de.
authors.forename: T
authors.initials: T
authors.lastname: Schaberg
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D019317:Evidence-Based Medicine; D006801:Humans; D015995:Prevalence; D016896:Treatment Outcome; D032581:Tuberculosis Vaccines / Q000008:administration & dosage*; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D032581:Tuberculosis Vaccines
keywords: Bedaquiline; Delamanid; Fluoroquinolones; PA-824; Tuberculosis, multidrug resistant